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Serum resistin is causally related to 
mortality risk in patients with type 
2 diabetes: preliminary evidences 
from genetic data
Andrea Fontana1, Lorena Ortega Moreno2, Olga Lamacchia3, Concetta De Bonis2, Lucia 
Salvemini2, Salvatore De Cosmo4, Mauro Cignarelli3, Massimiliano Copetti1, Vincenzo 
Trischitta2,5 & Claudia Menzaghi  2
Resistin has been firmly associated with all-cause mortality. We investigated, whether, in patients with 
type 2 diabetes (T2D), this association is sustained by a cause-effect relationship. A genotype risk score 
(GRS), created by summing the number of resistin increasing alleles of two genome-wide association 
studies (GWAS)-derived single nucleotide polymorphisms (SNPs), serum resistin measurements and all-
cause death records were obtained in 1,479 (403 events/12,454 person-years), patients with T2D from 
three cohorts, Gargano Heart Study-prospective design (n = 350), Gargano Mortality Study (n = 698) 
and Foggia Mortality Study (n = 431), from Italy. GRS was strongly associated with serum resistin in 
a non-linear fashion (overall p = 3.5 * 10−7) with effect size modest for GRS = 1 and 2 and much higher 
for GRS >3, with respect to GRS = 0. A significant non-linear association was observed also between 
GRS and all-cause mortality (overall p = 3.3 * 10−2), with a low effect size for GRS = 1 and 2, and nearly 
doubled for GRS ≥ 3, with respect to GRS = 0. Based on the above-reported associations, each genetic 
equivalent SD increase in log-resistin levels showed a causal hazard ratio of all-cause mortality equal 
to 2.17 (95%CI: 1.22–3.87), thus providing evidence for a causal role of resistin in shaping the risk of 
mortality in diabetic patients.
Resistin is a 12.5 kDa cysteine-rich pro-inflammatory1–3 and pro-atherogenic protein4–12, which in humans, is pri-
marily secreted by macrophages13 and firmly associated with all-cause mortality in several clinical sets including 
type 2 diabetes (T2D)14–25. Given the above-mentioned background and the deleterious role of resistin on several 
mortality risk factors26–28, it is conceivable that its association with mortality rate is sustained by a cause-effect 
relationship. However, no studies have so far addressed this hypothesis.
Genetic variants, robustly affecting an exposure, which in turn is associated to a given outcome, are 
easy-to-use tools for assessing if causality underlies the association of interest29–31. In our case, if genetic variants 
strongly linked to circulating resistin levels prove to be also associated with all-cause mortality, a strong case is 
made in favor of a causal role of resistin on all-cause death.
Few genome-wide association studies (GWAS) on circulating resistin have been conducted so far32–34. Two 
of them were carried out in Asians and pointed to the RETN locus as a major determinant of resistin levels33, 34. 
In contrast, in GWAS carried out in individuals of European ancestry we have recently shown that two different 
single nucleotide polymorphisms (SNPs), namely rs3931020 and rs13144478, in TYW3/CRYZ and NADST4 loci 
respectively, are associated with serum resistin32. Then, in order to investigate whether or not the association 
between resistin and all-cause mortality previously reported in European patients with T2D14–17, 22 is sustained 
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by a cause-effect relationship, a genotype risk score (GRS) based on these two SNPs, was created and used as 
an instrumental variable. It is of note that study patients here analyzed are from the same geographical region 
of some non-diabetic individuals previously investigated in the GWAS on serum resistin, pointing to both 
rs3931020 and rs1314447832.
Results
Clinical features of patients from Gargano Heart Study- (GHS)-prospective design, Gargano Mortality Study 
(GMS) and Foggia Mortality Study (FMS) as well as duration of follow-up and number of events are summarized 
in Table 1. The three samples were quite different in terms of most clinical variables (p < 0.05), but smoking 
habits.
In each cohort, as well as in the combined sample comprising 1,479 individuals (403 deaths/12,454 person 
years), each SD increase of log-resistin levels was significantly associated with all-cause mortality (Table 2). 
In each cohort as well as in the combined sample, such association was log linear. Similar associations were 
obtained after taking into account sex, age at recruitment, smoking habits, BMI, HbA1c, anti-hypertension and 
anti-dyslipidemia therapies, all being general risk factors shaping the risk of mortality rate (Table 2).
In all three cohorts, both SNPs tended to be associated with circulating resistin levels, though reaching statis-
tical significance only in GMS and FMS (Supplementary Table S1); in contrast, such association became stronger 
and statistically significant, in the combined sample after ascertaining the absence of a between-study heteroge-
neity (Supplementary Table S1).
To obtain a powerful instrumental variable (IV), able to address the causal nature of the relationship between 
serum resistin and all-cause mortality, an individual genotype risk score (GRS) was then created by simply sum-
ming the number of resistin increasing alleles, carried by each subject. In the combined sample, 231, 587, 599, 60 
and 2 individuals carried 0, 1, 2, 3 and 4 risk alleles, respectively. Individuals carrying 3 and 4 risk alleles were then 
pooled and considered together for further analyses.
When evaluating the association with circulating resistin levels, GRS was treated as categorical variable 
because of smallest achieved Alkaike information criterion (AIC) with respect to GRS treated as continuous 
variable (fully adjusted AIC = 3697 vs. 3708, respectively). Indeed, categorical GRS was strongly associated with 
GHS (n = 350) GMS (n = 698) FMS (n = 431)
Males (%) 238 (68.0) 344 (49.3) 224 (52.0)
Age at recruitment (yrs) 64.5 ± 8.2 61.3 ± 9.9 63.2 ± 11.6
Smokers (%) 58 (16.6) 102 (14.6) 71 (16.5)
Diabetes duration (yrs) 13.9 ± 9.2 10.3 ± 8.8 13.1 ± 10.1
BMI (kg/m2) 30.1 ± 4.8 31.0 ± 5.7 30.0 ± 6.1
HbA1C (%), (mmol/mol) 8.6 ± 1.9, (70 ± 20.8) 8.7 ± 2.0, (72 ± 21.9) 9.1 ± 2.2, (76 ± 24.0)
Insulin (w/wo) oral agents (%) 191 (54.6) 271 (38.8) 157 (36.4)
Anti-hypertension therapy (%) 296 (84.6) 323 (46.3) 291 (67.5)
Anti-dyslipidemia therapy (%) 227 (64.8) 195 (27.9) 162 (37.6)
Resistin (ng/ml) 10.7 ± 6.7 10.1 ± 8.1 8.5 ± 6.2
Follow-up (yrs), (py) 5.4 ± 2.5; (1,890) 10.8 ± 3.5; (7,504) 7.1 ± 2.5; (3,060)
Events (n) 78 206 119
IR (n. events per 100 py) 4.1 2.7 3.9
Table 1. Clinical characteristics of study patients. Continuous variables were reported as mean ± SD whereas 
categorical variables as total frequency and percentages. GHS: Gargano Heart Study; GMS: Gargano Mortality 
Study; FMS: Foggia Mortality Study; BMI: body mass index; HbA1c: glycated haemoglobin; IR: incidence rate 
of all-cause death events; py: person-years.
GHS (N = 350) GMS (N = 698) FMS (N = 431) Combined (N = 1,479) Between-study 
heterogeneityHR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Model 1 1.55 (1.27–1.90) 1.9 * 10−5 1.38 (1.21–1.57) 2.3 * 10−6 1.31 (1.11–1.56) 2.0 * 10−3 1.39 (1.27–1.53) 2.4 * 10−12 4.2 * 10−1
Model 2 1.64 (1.31–2.05) 1.5 * 10−5 1.30 (1.14–1.49) 6.9 * 10−5 1.17 (0.98–1.40) 8.0 * 10−2 1.31 (1.19–1.44) 2.5 * 10−8 2.1 * 10−1
Model 3 1.60 (1.26–2.02) 1.0 * 10−4 1.29 (1.11–1.49) 9.0 * 10−4 1.11 (0.92–1.33) 2.7 * 10−1 1.27 (1.14–1.41)§ 2.1 * 10−5 7.7 * 10−2
Table 2. Association between serum resistin and all-cause mortality in individual studies and in the combined 
sample. GHS: Gargano Heart Study; GMS: Gargano Mortality Study; FMS: Foggia Mortality Study. HRs (95% 
CI) are given for the increase of 1 SD of log transformed values of serum resistin. Model 1: unadjusted in 
individual studies and adjusted for study sample (i.e. GHS, GMS and FMS) in the combined analysis. Model 2: 
adjusted for sex, age at recruitment, smoking habits, BMI and study sample in the combined analysis. Model 
3: adjusted for sex, age at recruitment, smoking habits, BMI, HbA1c, anti-hypertension and anti-dyslipidemia 
therapies and study sample in the combined analysis. §Robust 95%CI confidence interval (due to the presence of 
between-study heterogeneity, i.e. for p < 0.10).
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serum resistin (overall p value = 3.5 * 10−7), with effect size being modest for 1 and 2 and much higher for >3 risk 
alleles, as compared to GRS = 0 (Supplementary Table S2, left panel).
Also when evaluating all-cause mortality, GRS was treated as categorical, rather than a continuous variable, 
with fully adjusted AIC being 1864 vs. 1867, respectively. Categorical GRS was associated with all-cause mor-
tality rate (overall p value = 3.3 * 10−2), with effect size being modest for 1 and 2 and much higher for >3 risk 
alleles with respect to GRS = 0 (Supplementary Table S2, right panel). Interestingly, both serum resistin means 
and mortality rates increased in the same magnitude when the number of GRS risk allele increases. In fact, the 
effect of increasing number of risk alleles on serum resistin (expressed as percent increase vs. individuals with 0 
risk alleles) paralleled that on mortality risk, (expressed as hazard ratio using individuals with 0 risk alleles as the 
reference group) (Fig. 1), clearly suggesting that the two associations are biologically related.
It is of note that GRS was not associated with any confounder (i.e. age at recruitment, sex, smoking habits, 
BMI, HbA1c, anti-hypertension and anti-dyslipidemia therapies) we accounted for, when testing the association 
between resistin and mortality rate (p values ranging from 0.13 to 0.64).
In subsidiary analyses, we noted that homozygotes risk allele carriers of either rs3931020 or rs13144478 had 
the highest effect size both on resistin levels and mortality rate as compared to the other genotype groups (data 
not shown), thus confirming that both SNPs contributed to the associations we here report for GRS group 3.
For each genetic equivalent standard deviation (SD) increase in log-resistin levels, a causal hazard ratio (HR) 
of all-cause mortality equal to 2.17 (95%CI: 1.22–3.87) was found. Such estimate was different, (fully adjusted p 
from Cochran Q test = 7.3 * 10−2), from the actual HR of the association between serum resistin and all-cause 
mortality (i.e. HR = 1.27; 95%CI: 1.14–1.41).
Discussion
Several studies have repeatedly reported resistin associated with mortality rate14–25. In this study we have now 
addressed whether in patients with T2D this association is sustained by a cause-effect relationship. Our present 
data show that a GRS, based on genetic variants strongly associated with serum resistin in Europeans32, is also 
associated with all-cause mortality. According to the use of genetic variants as a tool to address causality29–31, our 
finding provides, to the best of our knowledge, the first evidence for a possible causal association between resistin 
and all-cause mortality. This scenario is further supported by the observation that the relationships of GRS with 
serum resistin concentration on the one hand and risk of all-cause death on the other were both non-linear and 
parallel to each other. The lack of linearity of such associations, as well as the one between resistin circulating 
levels and all-cause mortality previously reported17 (that, in fact, we here confirm), deserves further, specifically 
designed, investigations to be addressed.
Of note, the GRS we used was based on two SNPs that are not only associated with circulating resistin in 
Europeans, but also with resistin gene (RETN) mRNA levels32, thus reinforcing its biological meaning and in a 
broader sense, our study design.
As suggested by Cochran Q-test <0.10, the genetic equivalent HRs of one SD increase in log-resistin levels 
for all-cause mortality was higher than the observed one (i.e. 2.17 vs.1.27, an approximately threefold differ-
ence on a log scale). Such discrepancy may be explained by the difference between a totally stable genetic effect, 
Figure 1. Plots of percentage changes in the estimated log-resistin means (circles) and HRs (squares), along 
with error bars which represented 95% CI of each percentage change at issue and of HRs, respectively. Both 
percentage changes and HRs were estimated taking into account GRS = 0 as the reference group. Error bars for 
percentage changes in log-resistin means were referred to the approximated standard errors derived using delta 
method (Supplementary Information).
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 61  | DOI:10.1038/s41598-017-00138-3
operating since birth on the one hand and, conversely, the effect exerted by serum resistin, evaluated only for the 
few years of our follow-up, with presumably highly variable levels, especially in heavily treated patients as are 
those with T2D35, 36. In addition, although no genome-wide data have reported the involvement of TYW3/CRYZ 
and NADST4 loci in risk factors for death, (http://www.gwascentral.org/), we cannot entirely exclude that these 
two loci exert, beside those on serum resistin, additional, still unknown, effects, somehow related to the risk of 
mortality.
Although the biology underlying the association between resistin and mortality rate has not been specifically 
addressed in this study, one can easily speculate that it is mediated by the deleterious effect exerted by resistin 
on intermediate metabolism, low-grade inflammation and atherosclerotic processes1–12 all established mortality 
risk factors. Another limitation of our study is represented by the lack of C-reactive protein and/or leukocyte 
measurements, two established risk factors, which would have helped clarify the pathway linking resistin and 
mortality rate.
We like to acknowledge that a great caution is needed in interpreting our data, which though of interest and 
entirely novel, cannot be considered as established. In fact, although, the sample we analyzed comprises more 
than 1,400 individuals with a total of 403 incident cases, the p values we obtained does not allow to exclude the 
possibility of a false positive result.
Moreover, a clear baseline clinical heterogeneity across the three study cohorts was evident. Also mortality rate 
was different across samples. Despite this, no difference was observed in the resistin effect on all-cause mortality, 
thus making unlikely that such heterogeneity have played a role in confounding our results. Nonetheless, when 
running pooled analyses, we were conservative enough to adjust for “study sample”, thus taking into account all 
baseline differences.
In addition, very likely because of the sub-cultured, mostly rural area as the one where our cohorts have been 
recruited, the proportion of patients treated at time of enrollments with insulin and/or anti-hypertensive and 
statins were lower than hoped. We cannot exclude that these baseline conditions, which luckily enough has being 
slowly changing in the last few years, may have affected the results obtained.
We also acknowledge that it remains to be investigated whether our finding applies also to non-diabetic indi-
viduals and whether it is extendible to populations of non-European ancestry with different environmental and 
genetic background which are known to affect serum resistin concentration37.
In conclusion, our data strongly point to resistin as a causal risk factor for all-cause mortality in T2D. Further 
confirmatory studies are needed before this finding may be considered as established. Additional studies are 
also necessary to verify whether adding resistin to previously validated tools38, 39 improves the ability to predict 
mortality rate in T2D and to explore if treatments aimed at reducing resistin levels36, 40, 41 also decrease the risk of 
death in such patients.
Methods
Patients. Three cohorts of patients with T2D (ADA 2003 criteria) from Apulia, central-southern Italy 
have been analyzed: the GHS-prospective design14, 15, 42–46, the GMS14, 15, 17, 38, 47 and the FMS)17, 38, 45, 47, (see 
Supplementary Information for details).
Clinical data were obtained from a standardized interview and examination as previously described14, 15, 17, 38, 
42–45, 47. Serum resistin was measured by a commercial ELISA (Bio Vendor, Brno Czech Republic) as previously 
described48 in 350 (95.2%) participants of GHS, 698 participants (67.9%) of GMS and 431 participants (37.4%) of 
FMS, constituting the eligible samples for the present analysis.
The study protocols and the informed consent procedures were approved by the Institutional Ethic Committee 
of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) “Casa Sollievo della Sofferenza” and the University 
of Foggia, respectively. All participants gave written informed consent. All methods were carried out in accord-
ance with the approved guidelines.
Genotyping. SNPs rs3931020 and rs13144478 were genotyped by Taqman SNP allelic discrimination tech-
nique by means of an ABI 7000 (Applied Biosystems, Foster City, CA) as previously described32, 49. Call rate and 
concordance rate were ≥96 and >99%, respectively.
The SNPs were in Hardy–Weinberg equilibrium (HWE) with the exception of rs3931020, p = 0.03 in FMS.
Statistical methods. Patients’ baseline characteristics are reported as mean ± standard deviation (SD) and 
percentages for continuous and categorical variables, respectively.
The relationship between resistin serum concentrations and all-cause mortality was log linear, as assessed 
by the Kolmogorov-type supremum test based on a sample of 10,000 simulated residual patterns50 and by visual 
inspection of residual pattern plots. Then, resistin levels were firstly normalized by a logarithm transformation 
and hence divided by its SD (i.e. log-resistin levels), in order to increase its clinical interpretability.
Detailed statistical methods used to assess associations between circulating resistin levels, SNPs and all-cause 
mortality risk, and to perform instrumental variable (IV) analysis, were reported in Supplementary Information.
Our combined sample of 1,479 patients with the observed mortality rate, achieves 80% power (assuming a 
type I error of 5%) to detect HRs of 1.15 and 1.19 for each unitary increase of one SD in log-resistin levels and 
for each unitary increase of GRS, respectively. Furthermore, this pooled sample achieves 80% power to detect a 
regression slope of 0.10 in SD-rescaled log-resistin levels for each unitary increase of one risk allele in GRS.
For all statistical analyses, a two-sided p-value < 0.05 was considered as significant, except when the effect of 
each SNP on serum resistin levels was evaluated (Supplementary Table S1). In this case, a Bonferroni-adjusted 
p-value < 0.025 was considered for statistical significance. All analyses were performed using SAS v.9.4 (SAS 
Institute, Cary, NC). Plots were produced using Comprehensive R Archive Network (CRAN) version 3.2.
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